The Latest Cardiac and Vascular News
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company specializing in innovative therapies for vascular disease, is pleased to announce the appointment of Andrew Davis as its new Chief Commercial Officer, effective immediately. “I am excited to join Endologix at such a pivotal moment” Post this Andrew joins […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced the final 36-month results of the DETOUR2 Study. The DETOUR System offers a unique approach to treating complex peripheral arterial disease (PAD), enabling physicians to […]
May 13, 2024 08:00 AM Eastern Daylight Time IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has announced the online publication of the one-year results of the DETOUR2 Trial in the Journal of Vascular Surgery […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced that Matt Thompson, President and CEO, will present at the Life Science Intelligence (LSI) USA ’24 Emerging Medtech Summit. Scheduled for March 20, 2024, at 10:55 am PT on Track 3, Thompson will offer insights into the company’s innovative portfolio and its impact on vascular disease trea
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately. With a distinguished 30-year career in leading commercial organizations within the cardiovascular arena, […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today the initiation of the PTAB1 Post-Market Study. This study marks the beginning of a comprehensive post-market study aimed at evaluating the real-world performance of the […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Art Taylor has been appointed to the Endologix Board of Directors. “Art’s wide-ranging experience in the healthcare sector adds a remarkable depth […]
IRVINE, Calif.–(BUSINESS WIRE)– Endologix Inc. LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Scott Ward has been appointed to the Endologix Board of Directors. Scott Ward was most recently the CEO and Chairman of the […]
IRVINE, Calif.–(BUSINESS WIRE)– Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announces that the U. S. Centers for Medicare & Medicaid Services (CMS) granted a Transitional Pass-Through (TPT) Payment for the DETOUR System, effective January 1, 2024. The TPT Payment […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced results from a pooled analysis of DETOUR1 and DETOUR2 Studies evaluating Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System. PTAB with the DETOUR System offers a novel approach to treating complex PAD, enabling physicians to bypass lesions in the superficial femoral art
